- Home
- ANGH vs BNR Comparison
ANGH vs BNR Comparison
Compare ANGH & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGH
- BNR
- Stock Information
- Founded
- ANGH 2012
- BNR 2014
- Country
- ANGH United Arab Emirates
- BNR China
- Employees
- ANGH N/A
- BNR N/A
- Industry
- ANGH Telecommunications Equipment
- BNR Medical Specialities
- Sector
- ANGH Consumer Discretionary
- BNR Health Care
- Exchange
- ANGH Nasdaq
- BNR Nasdaq
- Market Cap
- ANGH 32.1M
- BNR 38.3M
- IPO Year
- ANGH N/A
- BNR 2020
- Fundamental
- Price
- ANGH $3.30
- BNR $9.39
- Analyst Decision
- ANGH
- BNR
- Analyst Count
- ANGH 0
- BNR 0
- Target Price
- ANGH N/A
- BNR N/A
- AVG Volume (30 Days)
- ANGH 292.5K
- BNR 76.7K
- Earning Date
- ANGH 08-26-2025
- BNR 08-25-2025
- Dividend Yield
- ANGH N/A
- BNR N/A
- EPS Growth
- ANGH N/A
- BNR N/A
- EPS
- ANGH N/A
- BNR N/A
- Revenue
- ANGH $78,093,405.00
- BNR $72,112,038.00
- Revenue This Year
- ANGH N/A
- BNR $136.32
- Revenue Next Year
- ANGH N/A
- BNR N/A
- P/E Ratio
- ANGH N/A
- BNR N/A
- Revenue Growth
- ANGH 88.72
- BNR 0.53
- 52 Week Low
- ANGH $2.53
- BNR $2.18
- 52 Week High
- ANGH $9.46
- BNR $10.78
- Technical
- Relative Strength Index (RSI)
- ANGH 39.65
- BNR 70.28
- Support Level
- ANGH $3.19
- BNR $6.66
- Resistance Level
- ANGH $3.52
- BNR $7.15
- Average True Range (ATR)
- ANGH 0.46
- BNR 0.89
- MACD
- ANGH -0.00
- BNR 0.23
- Stochastic Oscillator
- ANGH 43.75
- BNR 70.20
About ANGH Anghami Inc.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. It generates the majority of its revenue from subscriptions.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.